Arcus Biosciences (RCUS) EPS (Weighted Average and Diluted) (2019 - 2026)
Arcus Biosciences' quarterly EPS (Weighted Average and Diluted) came in at -$1.02 in Q1 2026, up 10.53% year-on-year from -$0.92 in Q1 2025, and down 13.33% quarter-over-quarter from -$0.9 in Q4 2025.
Arcus Biosciences has reported EPS (Weighted Average and Diluted) for 8 years, with the latest figure at -$1.02 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 10.53% year-over-year to -$1.02; the trailing twelve-month figure through Mar 2026 stood at -$3.19 (up 23.87% YoY), and the FY2025 full-year result was -$3.29, down 4.78% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$1.02, down from -$0.9 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.05 in Q1 2024, with the low at -$1.27 in Q3 2025.
- Average EPS (Weighted Average and Diluted) over 5 years is -$0.96, with a median of -$1.01 recorded in 2024.
- Year-over-year, EPS (Weighted Average and Diluted) soared 95.41% in 2024 and sank 2180.0% in 2025.
- Tracing RCUS's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.93 in 2022, then dropped by 16.13% to -$1.08 in 2023, then advanced by 4.63% to -$1.03 in 2024, then rose by 12.62% to -$0.9 in 2025, then retreated by 13.33% to -$1.02 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.02 (Q1 2026), -$0.9 (Q4 2025), and -$1.27 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - | -1.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.02 |
| Dec 31, 2025 | -0.90 |
| Sep 30, 2025 | -1.27 |
| Mar 31, 2025 | -1.14 |
| Dec 31, 2024 | -1.03 |
| Sep 30, 2024 | -1.00 |
| Jun 30, 2024 | -1.02 |
| Mar 31, 2024 | -0.05 |
| Dec 31, 2023 | -1.08 |
| Sep 30, 2023 | -0.94 |
| Jun 30, 2023 | -1.04 |
| Mar 31, 2023 | -1.09 |
| Dec 31, 2022 | -0.93 |
| Sep 30, 2022 | -0.90 |
| Jun 30, 2022 | -0.93 |
| Mar 31, 2022 | -0.96 |
| Dec 31, 2021 | 3.99 |
| Sep 30, 2021 | -1.11 |
| Dec 31, 2020 | -0.87 |
| Sep 30, 2020 | 0.03 |
| Dec 31, 2019 | -0.37 |
| Sep 30, 2019 | -0.51 |